FDA granted Gene therapy Luxturna for vision loss and blindness

The FDA panel approved new gene therapy Luxturna. The treatment for Leber congenital amaurosis (LCA) an inherited retinal disease caused by defects in a gene called RPE65. Parents can unknowingly carry the flawed gene for generations.

Patients with a rare inherited form of blindness could be able to regain their sight if the Food and Drug Administration approves an experimental gene therapy in January.


(Visited 26 times, 1 visits today)

You might be interested in


Your email address will not be published. Required fields are marked *